In this article we will review available evidence concerning the effects of forebrain catecholaminergic and cholinergic activity on verbal perseveration. The anatomy and physiology of these two major neuropharmacological systems make it likely that they influence speech and language functioning directly as well as the cognitive systems that have an indirect impact on speech and language functions. Both catecholaminergic and cholinergic agents have been shown to influence executive cognitive functions (ECFs) such as ''resistance to interference'' and ''attentional switching'' as well as mnemonic encoding and retrieval processes. The ECF effects are most likely mediated by prefrontal cortex; mnemonic processes are mediated by both prefrontal and temporal lobes. Although no full-scale clinical trials on the effects of pharmacological agents on verbal perseveration have been conducted as yet, existing preclinical trials suggest that both presynaptic and postsynaptic dopaminergic agents can reduce perseverative responding by increasing inhibitory control processes. Cholinesterase inhibitors and other cholinergic agents can reduce perseverative responding by reducing verbal intrusions.
The term perseveration refers to the inappropriate repetition of an earlier response. With respect to speech and language deficits, Albert and Sandson 1 noted that most forms of verbal perseverative errors could be classified into one of three major categories: continuous, stuck-in-set, or recurrent.
Continuous perseveration is defined as the inappropriate prolongation or continuation of a response beyond the point of completion as if a normal stop signal were missing or no longer functional. 1 A patient may, for example, add extra loops when writing the letter m. Stuckin-set perseveration is the inappropriate maintenance of a framework of response after introduction of a new task, as when a patient continues to sort cards by an old rule (color) rather than by the new rule (shape) on the Wisconsin Card Sort (WCS) task. 1 Recurrent perseveration is defined as the inappropriate occurrence of part or all of a previous response after a different intervening stimulus or response. 1 Recurrent perseveration is likely to be the most prevalent form of perseveration in the realm of speech or verbal fluency as one can easily imagine inappropriate repetition of phonemes, morphological endings, or even whole words or phrases in patients with impairment to language areas of the brain. Whereas continuous perseveration might be suggested by phenomena such as ''press of speech,'' its detection in the speech signal at the whole word or sentential level would likely require temporal acoustic measurement. Similarly, stuck-in-set perseveration is less likely to be detected in sentences and words than in longer samples of discourse that reflect changes in conceptual content. To date, most studies that have addressed the issue of pharmacological effects on measures of verbal perseveration have confined themselves to the word or sentence level, and thus most of the data available for review in this paper concerns the effects of pharmacological agents on recurrent verbal perseveration.
Perseverative responding is common in disorders of speech and language. Depending on the study, between 50 and 90% of errors on verbal tasks made by patients with aphasia (regardless of type of aphasia) have been reported as perseverative, typically of the recurrent type. [2] [3] [4] Perseverative errors are also common in the speech of patients with senile dementia of the Alzheimer type, 5 schizophrenia, 6, 7 subcortical dementia (e.g., Parkinson's disease [PD] and Huntington's disease), [8] [9] [10] and vocal tics of Tourette's syndrome 11 and in patients with traumatic brain injury. 12, 13 Many of the repetitions and dysfluency associated with stuttering might be considered perseverative as well.
14 Successful therapeutic targeting of perseverative responding in disorders with speech and language deficits could potentially improve communicative abilities in all of these patient groups.
To our knowledge, no full-scale clinical trial of any pharmacological agent targeted specifically at reducing perseverative responding in disorders that show evidence of verbal perseveration has been conducted as yet. This situation is unfortunate, because existing research indicates that pharmacological approaches to reduction of perseverative responding in the verbal sphere may be effective, especially when combined with speech and language therapy. In this article, we review selected topics in the pharmacology of verbal perseveration with the aim of increasing the pace and quality of research in the field.
We focus here on the catecholaminergic and cholinergic systems, because these have been the most intensely studied. The serotonergic system is known to affect perseverative behavioral responding in children with pervasive developmental disorders, 15 but it may not improve and may even worsen perseverative behavioral responding in adults with intellectual disability. 16 The serotonin system may also influence what might be called ''internal perseverative verbal responding'' or rumination in depressive disorders, because ruminators commit more perseverative errors on the WCS task than do nonruminators. 17 In what follows, we review the chemical and functional neuroanatomy of the acetylcholine (ACh), dopamine, (DA) and noradrenergic (NE) systems insofar as they might influence language areas of the brain and verbal perseveration. We next briefly review studies of the effects of these neurochemical systems on fundamental cognitive mechanisms that are thought to influence verbal perseveration, particularly the executive functions, such as working memory, planning, shifting of cognitive sets, and attentional processes. We then focus on specific pharmacological effects on verbal perseveration, highlighting where necessary, neuromodulatory influences on speech and language processes associated with perseveration, such as verbal fluency and naming. We conclude with recommendations for further research in the pharmacology of perseveration.
NEUROANATOMY OF ACETYLCHOLINE
The major forebrain source of cholinergic innervation comprises nuclei of the basal forebrain, including the nucleus basalis of Meynert (nbM), the horizontal and vertical diagonal bands of Broca, the substantia innominata, and the medial septal nucleus. [18] [19] [20] [21] [22] Considered together, they are called the basal forebrain cholinergic system, and it is this collection of nuclei (especially the nbM) that is associated with profound degeneration in Alzheimer's disease. 23, 24 A second group of cholinergic neurons is found in the brainstem in the vicinity of the pedunculopontine tegmental nucleus and the laterodorsal pontine tegmentum.
Although most basal forebrain cholinergic neurons project diffusely throughout the cortex, they receive inputs from only a few major areas, including the reticular activating system (RAS), the limbic system, and orbitofrontal cortex. 20 In nonhuman primates, ACh fibers densely innervate motor, premotor, and temporal association cortices. Activation studies have shown that ACh cells projecting into temporal association cortex are physiologically heterogeneous, exhibiting diverse rates and patterns of firing and discharge. 25 Target areas of these ACh fibers may therefore be more controlled by individual ACh neurons, as compared with other modulatory transmitters that exhibit a less diverse set of modulatory controls than ACh neurons do. ACh also interacts with two major classes of receptors in cortical target areas: muscarinic and nicotinic.
Cholinergic activity may be greater on the left in the human brain. Amaducci et al 26 reported greater choline acetyltransferase (ChAT) activity in the left temporal lobes, as compared with the right, in the postmortem human brain. Glick et al 27 found evidence for greater ChAT activity in the left globus pallidus, as compared with the right, in the postmortem human brain. Hutsler and Gazzaniga 28 found that the density and distribution of ACh-containing axons and pyramidal cells vary systematically as a function of auditory processing level. Within primary auditory regions acetylcholineesterase (AChE)-containing axons are dense and pyramidal cells are largely absent. The putative language regions of posterior cortex outside of the primary auditory cortex contain a relatively high density of AChE-containing pyramidal cells and AChEcontaining axons. AChE-rich pyramidal cells of layer III were consistently greater in size in the left hemisphere as compared with the right, indicating perhaps an increased ACh influence on left-sided output processes of language regions of the brain. In summary, ACh-sensitive neurons are widely distributed throughout the brain, especially in neural networks underpinning speech and language and may, perhaps, be more prominently distributed in the left hemisphere.
NEUROANATOMY OF DOPAMINE
DA is manufactured in the pigmented neurons of the substantia nigra (SN) and the ventral tegmental area (VTA). There are three major ascending dopaminergic systems: the striatonigral tract, which ascends from the SN to the corpus striatum; the mesolimbic system, which ascends from the SN and medial VTA to limbic sites, including the cingulate gyrus; and the mesocortical system, which ascends from the anteromedial tegmentum and VTA to neocortical sites, including supplementary motor area (SMA) and prefrontal cortex. [29] [30] [31] [32] [33] Forebrain dopamine innervation decreases in a rostrocaudal gradient such that only trace amounts of DA are found in the occipital areas. The primary motor cortex exhibits the densest innervation pattern, with the supplementary motor area and prefrontal and inferior parietal areas following close behind. Thus, DA fibers preferentially innervate prefrontal, motor, and association areas in the cortex.
There is also evidence that dopaminergic activity may be greater on the left in human brain. Oke et al 34 and Glick et al 27 found greater catecholaminergic activity in left forebrain sites than in right-sided sites in the postmortem human brain. Berridge et al 35 have reviewed a wide range of evidence that demonstrates lateralization of stress-related activation of dopaminergic systems in the prefrontal cortex. For example, there is a greater reactivity of right-sided dopaminergic efferents in the prefrontal cortex during ''novelty stress'' (e.g., bright lights and white noise) in rats. Similar effects are found for stress associated with inescapable shock and other experimental paradigms. Given the well-known lateralization of affective processes (negative affect versus positive in right prefrontal regions versus left), 36 as well as cognitive processes (e.g., propositional speech output versus prosodic in left hemispheres versus right), in prefrontal cortices in humans, the asymmetric activity of dopaminergic systems in rats suggests (assuming that asymmetric effects are conserved in humans) that dopaminergic activity in left prefrontal networks may be able to modulate speech output functions. Dopaminergic activity in right prefrontal regions may be able to influence emotional, pragmatic, and prosodic functions.
NEUROANATOMY OF NOREPINEPHREINE
Noradrenergic innervation of the neocortex arises from the locus ceruleus (LC) in the pontine brainstem. 25, 31, 37, 38 Despite the relatively small number of neurons, the LC innervates every major region of the forebrain. Like DA, NE fibers run primarily in an anteroposterior plane. Individual neurons give off numerous collaterals innervating many different cortical regions. The primary somatosensory and motor regions are densely innervated in all six layers, but temporal and primary visual cortexes are more sparsely innervated. Note that this pattern complements that of ACh fibers, which project primarily to temporal and orbitofrontal cortices. Lesions of the dorsolateral prefrontal cortex are known to disinhibit firing of LC neurons and to impair regulation of the LC. Indeed, the prefrontal cortex may supply the only cortical afferents to the LC. [38] [39] [40] This anatomic arrangement suggests that the prefrontal cortex and the ascending noradrenergic system mutually influence their processing properties. Impairment in the functioning of one will affect the functioning of the other. Pharmacological agents that influence LC noradrenergic activity will also influence prefrontal functions, particularly those concerned with attentional processing and vigilance. 41 Although convincing evidence for lateralization of NE activity at the level of the cortex is, at present, lacking, participation of NE in the regulation of prefrontal functions and of attentional switching (discussed later) indicates that NE may be able to influence perseverative responding in the verbal sphere.
NEUROMODULATOR INTERACTIONS
Before turning to a consideration of pharmacological effects on cognitive functions implicated in verbal perseveration, we urge caution when interpreting results of the primary literature. Cognitive deficits, including perseverative deficits, are very likely not the result of single neurotransmitter effects. Rather, several neuromodulators probably interact and exert their effects via activation of relatively large regional brain systems, with subsequent modulation of specific neural circuits within those regions. These kinds of modulatory effects can only be accomplished via interactions among two or more modulatory substances. Some of the important neuromodulator interactions affecting cognitive performance involve cholinergicdopaminergic interactions, and cholinergicnoradrenergic interactions. 42, 43 For example, the combination of the noradrenergic agent clonidine and the anticholinesterase agent physostigmine enhances memory performance in aged monkeys to a greater degree than with either drug alone. 44 Friedman et al 45 have recently reviewed the evidence for an interaction of norepinephrine and cholinergic neurons in the pathophysiology of cognitive dysfunction in Alzheimer's and in schizophrenia. Clearly, neurotransmitter systems act in concert to support cognitive functions, and any drug given to influence one system will necessarily affect complementary systems. Thus, whenever we measure the effects of a given drug on a cognitive system, we have to assume that the drug is affecting more than one neurotransmitter system, even if the drug is considered to be a ''selective'' pharmacological agent.
INFLUENCE OF COGNITIVE FUNCTION ON VERBAL PERSEVERATION
One theory of verbal perseveration holds that verbal recurrences are a form of involuntary recall resulting from uncontrolled postactivation of normally inhibited memory traces. 46 This suggests that perseveration is essentially a failure of inhibition of normally inhibited memory traces or a failure to resist interference from activation of these normally inhibited memory traces. It is possible that unsuccessful attempts to access a target from the lexicon may trigger the activation of previous targets that have been strongly primed and have escaped suppression because of inhibition. The retrieval process would in this case be subject to the effects of interference from previously activated items. Given that inhibitory processes of the frontal lobes are implicated in control of ongoing cognitive operations it seems reasonable to suppose that dysfunction of executive control processes of the frontal lobes will play an important role in emergence of perseverative phenomena. Current neural network models of verbal and other forms of perseveration are consistent with these suppositions. 47 Cohen and Dahaene, 48 for example, proposed a model in which cognitive representations (such as lexical units) persist at relatively high activation levels for some time following initial activation. In healthy persons, persistence is overridden or suppressed via a competitive process between a new stimulus and the initial one when the new stimulus is presented. When brain damage degrades inhibitory powers of the frontal lobes, representations persisting in activity are not always effectively suppressed, resulting in perseveration. Gotts et al 49 pointed out that such a model predicts that factors that tip the balance of the competition in favor of the initial target versus a current stimulus that may override that target should increase perseverative responding because a weak current stimulus will be less likely to override a persistent initial stimulus.
Gotts et al 49 did in fact find that perseveration in aphasic individuals was more likely to emerge after they were presented with pictures of low-frequency items/names (a weak current stimulus) and semantically related items (strengthening initial stimulus). Perseveration also became less likely as the number of intervening trials (between an initial target and a current related stimulus) increased, presumably because the activation level of the initial stimulus weakened over time, thereby making it more vulnerable to being overridden by the current stimulus and frontal lobe inhibition.
Thus, current theory and some experimental evidence point to fundamental processes of inhibitory control including ''resistance to interference'' and ''attentional switching'' in production of verbal perseveration. Given that the prefrontal cortex is crucial for inhibitory control, it is not surprising that resistance to interference and attentional switching have also been linked to prefrontal systems. Interestingly, these prefrontally based cognitive processes are modulated primarily by catecholaminergic (NE and DA) activity, but cholinergic influences are important as well.
Prefrontal Dopamine Resistance to Interference and Attentional Switching Depletion of dopamine from prefrontal cortex induces cognitive deficit, as measured by delayed-response tasks. 50 Measurement of dopamine concentration within the prefrontal cortex of monkeys before and during performance of a delayed response task shows a significant increase in dopamine levels while the animals are engaged in the delay period. Injections of selective D1 receptor antagonists and nonselective D1 antagonists such as haloperidol (but not cholinergic or serotoninergic antagonists) in the monkey's prefrontal cortex induce deficits in the delayed response task that are dose dependent. The higher the dose, the worse the performance. Thus, dopamine appears to regulate directly ''the resistance to interference'' aspect of working memory capacity in the monkey. 51 Dopamine enhances working memory only within a certain limited concentration range, however. Higher or lower doses are associated with functional impairment.
Evidence for catecholaminergic activity on attentional switching comes from studies of attentional function in PD. These studies suggest that forebrain dopamine, in addition to cortical norepinephrine, is crucially involved in attentional switching. [53] [54] [55] There is, for example, a well-established PD attentional switching deficit on ''category alternation paradigms,'' in which patients are required to generate names in one category for about 1 minute and then switch to another category. 53, 56 PD patients find it difficult to generate an adequate number of names after switching categories. Administration of the dopaminergic drug levodopa protects against this switching deficit for many patients who exhibit the deficit.
54,57
Acetylcholine Resistance to Interference and Attentional Switching The anticholinergic drug scopolamine abnormally prolongs the event related potential (ERP) P300 wave (an index of attention) and slows reaction time. 58, 59 Anticholinergics impair performance for a variety of vigilance tasks, such as the continuous performance test; cholinomimetics have the opposite effect. 60 Cholinergic modulation of attentional switching and of vigilance is generally thought to be mediated by muscarinic receptors.
Noradrenergic Resistance to Interference and Attentional Switching
Discharge rates of LC neurons are increased by arousal and attentiveness. 25 Electrical stimulation of the LC produces a suppression of ongoing background cortical activity, thereby enhancing stimulus-evoked activity, resulting in enhanced signal to noise ratios in neuronal processing. The LC appears to be preferentially activated by novel stimuli. Once a novel or significant stimulus is detected, neuronal firing to non-novel stimuli is attenuated or suppressed, thereby focusing attention on taskrelevant behaviors. As mentioned earlier, lesions of the prefrontal cortex are known to disinhibit firing of LC neurons and to impair regulation of the LC. 38, 50, 61 This finding suggests that voluntary control of attentional switching may be mediated in part by descending fibers from prefrontal cortex onto noradrenergic neurons of the LC. Conversely, ascending noradrenergic fibers to prefrontal cortex may mediate processes of attentional switching, such as the rate at which attention is disengaged from the current task and then applied to the next task. The cognitive consequences of prefrontal dysfunction should therefore be associated with attentional dysfunction or with inability to suppress distracting or irrelevant stimuli. Drugs that activate prefrontal cortex (such as clonidine or Ritalin 1 ) should indirectly improve attentional function (through their effects on LC regulation).
Clinical studies of PD suggest that switching comes from cortical NE. 53, [62] [63] [64] Postmortem studies of cortical NE and methoxyhydroxyphenethyleneglycol (the major metabolite of NE), consistently show decrements of these chemical indices in PD patients with attentional dysfunction. 65 Stern et al 62 found significant correlations between NE metabolite levels in PD patients with performance on reaction time tasks and continuous performance tasks that measure attention and vigilance. More recently Riekkinen et al 64 reported significant correlations between measures of cerebrospinal fluid NE levels and attentional cognitive performance in PD.
PHARMACOLOGICAL EFFECTS ON EXECUTIVE COGNITIVE FUNCTIONS
Both attentional switching and resistance to interference have been linked to prefrontal systems and can be considered ''executive control functions.'' ECFs refer broadly to cognitive activity involving the planning, initiation, monitoring, and adjustment of nonroutine and goal-directed behaviors and are disproportionately impaired in disorders known to manifest varying levels of verbal perseveration. All of these executive control processes depend to some extent on the ability of the frontal lobes to exert inhibitory control at strategic points in an ongoing cognitive operation. To the extent, therefore, that catecholaminergic activity modulates prefrontal networks, drugs that affect catecholaminergic systems should influence ECFs and ultimately verbal perseveration.
Antidopaminergic antipsychotic agents, such as haloperiodol, are known to affect ECFs adversely in some patients with schizophrenia. 45 The atypical neuroleptics risperidone and clozapine have been shown to improve ECFs, as measured by verbal fluency tasks, 66 the digit span distractibility test, 67 and the Trails-B test. 68 Atypical neuroleptics may increase DA by antagonizing 5-HT2A receptors, which in turn activates dopaminergic neurons in the VTA. Interestingly, apart from verbal fluency, long-term administration of clozapine does not appear to improve ECFs in schizophrenics. 69, 70 Long-term administration of clozapine may result in excessive prefrontal cortical levels of dopamine, because clozapine is known to induce an increase in extracellular concentration of dopamine in the prefrontal cortex. 45, 71 Once again, we are confronted with evidence that pharmacological agents may improve selected cognitive functions but only within a limited dosage range; too much or too little, or the right amount for too long, can make things worse.
Levodopa, a dopaminergic drug used to treat PD, has been shown to significantly enhance performance of PD patients on ECF tests such as the WCS test, the Tower of London planning test, verbal fluency tasks, and forms of visuospatial functioning linked to ECFs. 52, 54, 57, 72 However, conflicting results abound in the research literature. There is, in fact, evidence that excessive levels of dopamine in the prefrontal cortex can impair prefrontal cognitive functions. 38, 45, 71 Nevertheless, there is clear evidence of a beneficial effect of levodopa (and therefore catecholaminergic activity) on ECFs. Kulisevsky et al 72 found significant decrements in executive functions (including the WCS test) of a group of PD patients displaying major medication-related fluctuations in motor control compared with those showing a good response to therapy. The decrements occurred when the patients were off levodopa. Similarly, Lange et al 54, 57 found that PD patients were dramatically impaired on ''frontal'' or executive function tests (Tower of London task, set shifting, working memory, and spatial attention span) only when withdrawn from L-dopa medication. Performance on non-frontally mediated tests, such as visual memory tests, was not impaired when patients were off levodopa.
In summary, both catecholaminergic agents and cholinergic agents have been shown to influence cognitive processes that likely affect the tendency for preservative responding. The effects are most likely mediated by prefrontal cortex and involve ECFs as measured by classic ECF tests such as the WCS test, the Tower of London test, delayed response paradigms, verbal fluency paradigms, and attentional switching paradigms. We turn now to a consideration of drug effects on specific measures of verbal perseveration. These effects, although undoubtedly mediated by prefrontally-based lapses in executive and inhibitory control, are nonetheless surprisingly autonomous and may not always vary with changes in ECF performance. The speech and language system is not simply parasitic on ''more fundamental'' cognitive processes but instead rests on dedicated neural machinery that, in concert with prefrontal ECF processing, supports fluent control of speech and language processing.
CHOLINERGIC EFFECTS ON VERBAL PERSEVERATION
Cholinergic effects on verbal perseveration can be studied in the speech samples of patients with Alzheimer's disease. Alzheimer's disease is associated with both ECF deficits and verbal perseverations. This dementia syndrome has been linked to a loss of cholinergic neurons in the nucleus basalis of Meynert and in other cholinergic sites that project to the medial temporal lobe, such as the diagonal band of Broca and the septal nucleus. 73 However, early attempts to treat the dementia of Alzheimer's disease by pharmacologically increasing cholinergic activity met with only modest success. [74] [75] [76] [77] This should not be surprising since several neurotransmitter systems are affected in Alzheimer's disease. 59 More recent attempts using cholinesterase inhibitors have met with only slightly greater success. Unlike other areas under investigation in the pharmacotherapy of cognition, methodological and experimental design issues in the study of Alzheimer's disease, such as the choice of objective outcome measures and recruitment of adequate numbers of research patients, have been frequently addressed, at least with respect to investigations of the effectiveness of anticholinesterase agents. A small number of large, multicenter, double-blind, placebo-controlled clinical trials have been conducted with these agents, 75, [78] [79] [80] [81] with modest positive treatment effects reported in most cases.
With respect to specific effects of cholinergic agents on verbal perseverations, few reliable data are available. Drachman et al 82 in 1974 found intrusions and perseverations in healthy nonaphasic subjects given the anticholinergic scopolamine. This finding suggests that recurrent perseveration may be associated with a specific cholinergic deficit. Thal et al 83 reported that six of eight patients with early Alzheimer's disease treated with oral physostigmine and supplementary lecithin demonstrated improvement in total recall and a decrease in verbal intrusions. Fuld et al 84 found that the occurrence of one or more intrusions (delayed recurrent perseverations) distinguished patients with Alzheimer's disease from patients with dementia of other etiology. In contrast, a cholinergic antagonist was reported to increase perseveration.
Tanaka et al 85, 86 have recently reported that cholinergic therapy significantly improves naming ability in both persons with dementia and in those with mild-to-moderate Wernicke's aphasia. Contrary to expectation, however, improvement in language function among those with aphasia was not related to improvement in verbal memory but was correlated with a reduction in perseveration. No improvement was seen in persons with severe aphasia. Willmes et al 87 conducted a double-blind, placebo-controlled pilot study in which patients with aphasia treated with piracetam showed greater improvement on certain subtests of the Aachen Aphasia Test than the control group did. In an earlier study, Tanaka et al 86 administered bifemelane, a cholinergic agent, to patients with aphasia and demonstrated a beneficial effect on naming ability. Aarsland et al 88 performed tests of reading, spelling, and oral language in 22 healthy women after administration of scopolamine to investigate the effect of cholinergic blockade on language. They found dose-dependent impairments in reading, spelling, verbal fluency, and object naming. Dubois et al 89 compared the neuropsychological performance of a group of 20 patients with PD treated with anticholinergic drugs with that of a group of 20 patients who received no anticholinergic drugs. Severe impairment on ECF tests was observed in the group receiving anticholinergic drugs. Presumably, verbal perseverations would be increased in this group as well.
CATECHOLAMINERGIC EFFECTS ON VERBAL PERSEVERATION
Very little direct information is available on dopaminergic or noradrenergic effects on verbal perseveration. Imamura et al 90 reported that bromocriptine (BRC) 10 mg/d was effective in reducing cognitive and verbal perseverations in some patients with vascular and degenerative dementia. We could find no other pharmacotherapeutic trials targeted specifically toward reduction of verbal perseveration. One may infer such effects, however, by looking at the influence of catecholaminergic agents on aspects of verbal fluency, such as verbal dysfluency, palilalia, repetitions, recurrent perseverations, and so on. 91 Very soon after the adoption of levodopa in the 1970s as the preferred treatment of motor symptoms of PD, it was noted that levodopa also seemed to have variable effects on speech fluency deficits in PD. [92] [93] [94] [95] Although some investigators reported little or no improvement of speech functions after levodopa, 94 others reported substantial improvement. 92, 93, 95 Critchley's 96 article in 1981 pointed to repetitive speech phenomena in PD patients and concluded that treatment with levodopa was sometimes associated with improved articulatory and phonologic aspects of PD speech. Recent investigations into the effects of levodopa on speech functions, however, have reported conflicting results. Reports citing beneficial effects of levodopa on certain measures of speech function in PD have continued to appear 97, 98 ; others report no effects 99 or even adverse effects. 100 Other catecholaminergic agents have been studied as well. An early study by Benson (reported only in abstract form) 101 claimed some success in treating aphasics with amphetamines. McNeil et al significantly improve lexical-semantic deficits in a patient with primary progressive aphasia. When combined with behavioral therapy, however, these deficits were significantly ameliorated relative to either drug or behavioral therapy alone. More recently, Walker-Batson 103 reported similar findings.
The D2 dopamine receptor agonist BRC has been used in case studies and small clinical trials for treatment of aphasic speech. To our knowledge, Albert and colleagues 104 were the first to report a patient with aphasia whose fluency improved after treatment with BRC. Gupta and Mlcoch 105 reported two patients with left frontoparietal infarcts and nonfluent aphasia. These patients were treated with BRC for 3 months and underwent comprehensive language testing before and during treatment. Both patients improved markedly in speech fluency but not in other aspects of language function. Sabe et al 106 conducted a prospective open-label trial of BRC in seven nonfluent patients with aphasia with left frontal infarcts. They treated patients with 30 to 60 mg/d of BRC. They reported statistically significant correlations between fluency measures and escalating doses, as well as between behavioral deterioration and declining doses of the drug. Unfortunately, although the trend in all of these studies suggests beneficial effects of BRC on fluency and naming tasks, firm conclusions are difficult to draw because none of these studies was adequately powered with suitable methodological controls.
Similarly, studies with more rigorous experimental protocols have also been underpowered. These studies reported mixed findings with respect to fluency and naming measures and BRC therapy. The double-blind, placebocontrolled study by Sabe et al 106 involving seven participants similarly did not show any significant effect of BRC on language measures. The dose of BRC was reported to be up to 60 mg/d, however, an amount that may act as a dopamine antagonist. In addition, the seven participants included both fluent and nonfluent aphasia types with mixed etiologies (i.e., cerebrovascular accident and closed head injury). Bragoni et al 107 used a double-blind, placebo-controlled design, focused only on patients with chronic nonfluent aphasia at a dosage of 30 mg/d, with participants maintained at that dosage for 3 months. Although significant gains in verbal fluency and naming were evidenced with BRC, these findings are based on the performance of only five participants. Gupta et al 108 used a double-blind, placebo-controlled crossover design in 20 participants with chronic nonfluent aphasia and found no significant effect of BRC on language abilities; however, the dose used was only 15 mg/d.
CONCLUSIONS
A coherent neurochemistry of perseveration is emerging. Basic research on neurobiological aspects of perseveration has clearly shown perseverative phenomena to be frequent correlates not only of cognitive dysfunction in Alzheimer's disease but also of fluency and naming problems in aphasia. Preliminary clinical studies on the pharmacotherapy of perseveration in Alzheimer's disease and aphasia are intriguing and promising. The field is ripe and ready for translational research carrying knowledge of cognitive and pharmacological aspects of perseveration from the laboratory to the clinic.
Studies that identify pharmacological effects on ECFs and other cognitive processes implicated in inhibitory control should lead to more effective and targeted pharmacological treatments of perseverative responding. Given that BRC has been reported to reduce perseverative responding in patients with dementia and to increase verbal fluency in patients with nonfluent aphasia, BRC or some other dopaminergic D2 agonist should be more intensely investigated as a potential pharmacological treatment for verbal perseveration. More information is needed on pharmacological effects on continuous and stuck-in-set perseveration in addition to recurrent forms. Pharmacological links between ''internal verbal perseverations'' and overt perseverations in neuropsychiatric disorders should be pursued as well. Findings from the literature on stuttering should be compared with those on aphasia and to those on disorders such as PD and schizophrenia to identify common pharmacological correlates of verbal dysfluency, insofar as these may have an impact on perseverative responding. Finally, results from theoretical modeling of verbal perseverations should be brought to bear on the design of pharmacological studies to better identify targets for pharmacological intervention and to improve our understanding of just how the complex process of speech and language processing is accomplished in the mind/ brain.
